Dr. Hussein Abdul-Hassan Tawbi on Oral Azacitidine Plus Pembrolizumab in Metastatic Melanoma

Video

Cancer Network spoke with Hussein Abdul-Hassan Tawbi, MD, PhD, on the results of a phase II study of oral azacitidine in combination with pembrolizumab in metastatic melanoma.

Cancer Network spoke with Hussein Abdul-Hassan Tawbi, MD, PhD, associate professor at The University of Texas MD Anderson Cancer Center, on the results of a phase II study of oral azacitidine in combination with pembrolizumab in patients with metastatic melanoma. The data (abstract 9560) were presented at ASCO 2019.

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Related Content